Background Our approach to the treatment of neurodegenerative disease is based on the understanding that normal neuronal function depends on physiological and biological interactions between the major cell types in the central nervous system: neurons, astrocytes, oligodendrocytes, and microglia. On the other hand, a disease process that was originally confined to the neuron may trigger unwanted activation of astrocytes and microglia leading to an accelerated loss of function and neuronal cell death.
Our aim is to develop broad-target therapies that activate multiple pathways within each target cell to stop the ongoing loss of synaptic function and prevent death of neuronal cells. Effective patient treatment should benefit from the simultaneous targeting of all cell types to not only arrest ongoing disease activity but also activate homeostatic and repair mechanisms.
Our drug development programs are based on the discovery of a novel class of endogenous (body-produced) mediators called resolvins and protectins, so named because they were found to accelerate resolution of inflammation and to protect the affected host tissue form cell death. Resolvins and protectins are continuously formed in the body from omega-3 fatty acids and support tissue and organ homeostasis. One particular group of protectins formed from DHA has proven to be particularly powerful regulators of neuronal homeostasis. Anida's lead compound, Neuroprotectin D1 (NPD1) is selected from this group of mediators.